Who are Ppsv23's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Prevnar 20, Streptococcus pneumoniae serotype 3, PPV23 alone, pneumococcal conjugate 13 valent vaccine, Prevnar family, Control 23-valent PPV.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ppsv23.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Ppsv23 — Competitive Intelligence Brief

Ppsv23 (ppsv23) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vaccine. Area: Immunology.

marketed Vaccine Streptococcus pneumoniae Immunology Vaccine Live · refreshed every 30 min

Target snapshot

Ppsv23 (ppsv23) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ppsv23 TARGET	ppsv23	Pfizer	marketed	Vaccine	Streptococcus pneumoniae
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
Streptococcus pneumoniae serotype 3	Streptococcus pneumoniae serotype 3	University of Oxford	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae serotype 3 capsular polysaccharide
PPV23 alone	PPV23 alone	Korea University Guro Hospital	marketed	Polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides (23 serotypes)
pneumococcal conjugate 13 valent vaccine	pneumococcal conjugate 13 valent vaccine	University of Siena	marketed	Conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (13 serotypes)
Prevnar family	prevnar-family	Pfizer Inc.	marketed	Vaccine	Streptococcus pneumoniae
Control 23-valent PPV	Control 23-valent PPV	Sinovac Biotech Co., Ltd	marketed	Pneumococcal polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides (23 serotypes)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (Vaccine class)

GlaxoSmithKline · 16 drugs in this class
Sanofi Pasteur, a Sanofi Company · 12 drugs in this class
Pfizer · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Henogen · 3 drugs in this class
Pfizer Inc. · 2 drugs in this class
Sanofi · 2 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 2 drugs in this class
BioNTech · 2 drugs in this class
Merck Sharp & Dohme LLC · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ppsv23 — Competitive Intelligence Brief. https://druglandscape.com/ci/ppsv23. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab